← back to search

Maeve O’Reilly

University College London Hospitals NHS Foundation Trust · GB
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, and Biosimilars and Bioanalytical Methods.
h-index
19
citations
2,919
works
120
NIH funding
primary concept
Medicine
email

Recent publications

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
Blood 2025cited by 8position: middledoi
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
Leukemia 2025cited by 7position: middledoi
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Journal of Hematology & Oncology 2024cited by 28position: middledoi
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Leukemia 2024cited by 10position: middledoi
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of Clinical Oncology 2023cited by 121position: middledoi
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma
Blood 2023cited by 69position: middledoi
A national service for delivering <scp>CD19 CAR‐T</scp>in large B‐cell lymphoma – The <scp>UK</scp> real‐world experience
British Journal of Haematology 2022cited by 109position: middledoi
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Journal of Clinical Oncology 2021cited by 138position: middledoi
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
Blood Advances 2021cited by 74position: middledoi
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Blood 2019cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Claire Roddie · Cancer Institute (WIA)3 papers (2021–2025) · 2 papers (2023–2025)Pere Barba · University College London2 papers (2023–2025)Gloria Iacoboni · IPO Porto2 papers (2023–2025) · 2 papers (2023–2025) · 2 papers (2023–2025) · 2 papers (2023–2025) · 2 papers (2023–2025)Lucía López‐Corral · Universidad de Salamanca2 papers (2023–2025)Kai Rejeski · Cornell University2 papers (2023–2025)Vı́ctor Navarro · Thomas Jefferson University2 papers (2023–2025) · 2 papers (2023–2025)Juan Luis Reguera · Hospital Universitario Virgen del Rocío2 papers (2023–2025) · 2 papers (2023–2025)Victoria Potter · King's College Hospital NHS Foundation Trust1 papers (2021–2021)George Petrides · University of Exeter1 papers (2021–2021)Alejandro Martı́n · Centro de Investigación Biomédica en Red de Cáncer1 papers (2025–2025)Tom van Meerten · The University of Texas MD Anderson Cancer Center1 papers (2025–2025)Piers Patten · King's College London1 papers (2021–2021) · 1 papers (2023–2023)